Daniel Barenboim, Parkinson's disease

Psychology Today22h
A Suggested Revolution in Parkinson’s Research
We spend billions searching for the cures to chronic illnesses while neglecting research that could make the daily lives of ...
She was diagnosed with Parkinson’s at 27. These were her warning signs.
People with early-onset Parkinson’s face challenges different from those with traditional late-onset Parkinson’s.
Drug Similar to Ozempic Failed to Treat Parkinson’s Disease in a Trial
The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...
MedPage Today15h
Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial?
The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Medscape5h
Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease
Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
MedPage Today2d
FDA OKs New Wearable Treatment for Parkinson's Disease
The FDA approved an apomorphine hydrochloride infusion device (Onapgo) to treat motor fluctuations in adults with advanced ...
FDA approves wearable infusion device for advanced Parkinson disease
The U.S. Food and Drug Administration has approved Onapgo (apomorphine hydrochloride) injection as the first and only ...
Sergey Brin’s $2 Billion Quest To Tackle Parkinson’s, Bipolar Disorder And Now Autism
The Google cofounder has donated more than $1.5 billion to Parkinson’s research. Now, as he takes on autism, he’s also ...